Sugi Predict

Sugi Predict / Compounds / SCHEMBL12409679

SCHEMBL12409679

SCHEMBL12409679

CNC(=O)c1ccc(-c2ccc(C)cn2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BAZ2B Q9UIF8 1/20 0.65
▸ MMP13 P45452 1/20 0.50
▸ ATM Q13315 2/20 0.49
▸ PTPN1 P18031 2/20 0.49
▸ PTPN6 P29350 1/20 0.49
▸ PTPN11 Q06124 1/20 0.49
▸ MKNK1 Q9BUB5 1/20 0.49
▸ MKNK2 Q9HBH9 1/20 0.49
▸ PLK1 P53350 1/20 0.48
▸ MCHR1 Q99705 1/20 0.47
▸ HDAC6 Q9UBN7 2/20 0.47
▸ CCR1 P32246 1/20 0.47
▸ CCR5 P51681 1/20 0.47
▸ CCR8 P51685 1/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PTPN2 P17706 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145174 0.83 BAZ2B (0.60) BAZ2BHDAC6CYP3A4CYP2A6HDAC8
SCHEMBL24365557 0.83 BAZ2B (0.60) BAZ2BHDAC6CYP3A4CYP2A6HDAC8
SCHEMBL15070399 0.82 P4HTM (0.50) BAZ2BPTPN1PTPN6PTPN11MCHR1
SCHEMBL31145162 0.81 SMN1; SMN2 (0.64) BAZ2BHDAC6CCR1CCR5CCR8
SCHEMBL4463638 0.81 SMN1; SMN2 (0.64) BAZ2BHDAC6CCR1CCR5CCR8
SCHEMBL15070386 0.81 NPC1 (0.56) MCHR1CNR1NPC1RAB9ASMN1; SMN2
SCHEMBL3066010 0.81 BAZ2B (0.54) BAZ2BCNR1CYP3A4CYP2A6
SCHEMBL15507078 0.81 BAZ2B (0.79) BAZ2BATMPTPN1PTPN6PTPN11
SCHEMBL4469903 0.81 TDP1 (0.59) BAZ2BATMHDAC6CCR1CCR5
SCHEMBL31145166 0.81 TDP1 (0.59) BAZ2BATMHDAC6CCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 — — US disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-11999727-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 — — CN disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
US-20230113778-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-11492350-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2022-11-08 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
WO-2022026892-A1 PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS TANGO THERAPEUTICS, INC. (US) 2022-02-03 — — WO disclosed
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 — — US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC BAZ2B 3679/4885MMP13 4625/4885ATM 1256/4885
US-11999727-B2 Compounds and methods of use F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-11492350-B2 Compounds and methods of use F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-20230113778-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-12264154-B2 Compounds and methods of use F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 BAZ2B 3817/4885MMP13 2801/4885ATM 3957/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 BAZ2B 3439/4885MMP13 2084/4885ATM 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.